ZURICH (Reuters) - Novartis said on Friday the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis. Ilaris inhibits interleukin-1 beta, excessive production of which plays a prominent role in certain inflammatory diseases, the company said. The drug is the only approved treatment specifically for the condition that can be given as a monthly subcutaneous injection, Novartis said. Ilaris is also approved in the European Union for the treatment of refractory gouty arthritis, Novartis said. (Reporting by Zurich Newsroom)
Courtesy of Yahoo News
No comments:
Post a Comment